Navigation Links
Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
Date:7/13/2012

AMSTERDAM, July 13, 2012 /PRNewswire/ --

Amsterdam Molecular Therapeutics (AMT) Holding NV (in liquidation) (Euronext: AMT) published its Annual Report and Accounts for the year ended December 31, 2011 and announced that it will host its Annual General Meeting at its headquarters (Meibergdreef 61, 1105 BA Amsterdam Zuidoost, the Netherlands) at 14.00 hrs on September 12, 2012. Shareholders of the dissolved company are invited to attend.

For further details, agenda and voting information, visit: http://www.amtbiopharma.com/investors/shareholder-information

About Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation)

On March 30, 2012, an extraordinary general meeting of shareholders approved a major corporate restructuring and financing transaction involving the disposal of AMT's entire business and operations to uniQure B.V. and the subsequent dissolution, liquidation and delisting of AMT. On April 5, the disposal completed and AMT's dissolution as resolved by the extraordinary general meeting of shareholders became effective, with Mr. Jörn Aldag and Mr. Piers Morgan being appointed as the liquidators charged with the liquidation of the company's dissolved property. On April 26, 2012, the liquidators made an advance distribution - consisting of depositary receipts for ordinary class B in uniQure B.V. - to AMT's shareholders. There will not be any further (final) distributions made to AMT shareholders.

AMT and the AMT shares will continue to exist until the liquidation is finalised, which is expected to occur before the end of 2012. AMT and its shares ceasing to exist upon the ending of the liquidation shall effectively also result in the delisting of AMT, to the extent the delisting cannot be achieved at an earlier date in consultation with Euronext Amsterdam and subject to such conditions as Euronext Amsterdam may propose.

Further information on AMT, can be found on AMT's website http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on current expectations only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT (in liquidation). Actual results could differ materially from current expectations due to a number of factors and uncertainties. AMT (in liquidation) expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.

PRN NLD


'/>"/>
SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. EHA Honorary Awards at the 17th Congress of EHA in Amsterdam
2. joimax® at the Early Summer Congresses: SpineWeek Amsterdam and DGNC Leipzig
3. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
4. BSGI Molecular Breast Imaging Proves Equivalent to MRI in Breast Cancer Patient Management
5. BSGI Molecular Breast Imaging Provides Better Results than MRI for Cancer Patients with Dense Breasts
6. The 2012 US Molecular Diagnostics Market
7. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
8. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
9. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
10. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
11. Echo Therapeutics Expands License Agreement with Ferndale Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Hypermarcas S.A. ("Hypermarcas") today announced that ... "Tender Offer") to purchase any and all of ... its 6.500% Senior Notes due 2021 (CUSIP Nos. ... "Notes"). In connection with the Tender Offer, Hypermarcas ... "Consents") of the holders of the Notes (the ...
(Date:2/12/2016)... 12, 2016 ... http://www.sedar.com ) und der ... abrufbar.    --> http://www.sedar.com ) ... http://www.telestatherapeutics.com abrufbar.    --> ... seinen Konzernabschluss des zweiten Quartals und ...
(Date:2/12/2016)... -- Memorial Hermann Health System has teamed up with Houston ... a one-of-a-kind experience to pediatric patients at Children,s ... 360-degree video and Google Cardboard, Howard was able to ... the patients and their families an unexpected, and energetically ... video . Memorial Hermann IRONMAN Sports ...
Breaking Medicine Technology:
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist ... Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. to volunteer at ... dental professionals, donating their time and skills to help hundreds of uninsured and underinsured ...
(Date:2/12/2016)... New York, NY (PRWEB) , ... February 12, ... ... latest edition of “Revolutionizing Cancer Care.” , The print component of ... in Chicago, Dallas, Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, Inc. ... and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health plans ... categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors ...
(Date:2/12/2016)... CA (PRWEB) , ... February 12, 2016 , ... US ... Des Moines, Iowa. Legacy Golf Club, located in Norwalk, serves as the host site ... the Year, Rob Randall. , “We have had successful camps in recent years around ...
Breaking Medicine News(10 mins):